← Back to Search

Other

IMG-007 for Alopecia Areata

Phase 1 & 2

Recruiting

Research Sponsored by Inmagene LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Male or female aged ≥ 18 and ≤ 65 years

AA with ≥ 50% scalp involvement as defined as SALT score ≥ 50

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, week 24

Awards & highlights

Study Summary

This trial investigates if a new drug is safe and effective for people with hair loss due to Alopecia Areata.

Who is the study for?

This trial is for adults aged 18 to 65 with Alopecia Areata (AA) who have lost more than half of their scalp hair for over 6 months but less than 8 years. Candidates should not have active infections, hepatitis B/C, HIV, TB, or other conditions that cause hair loss or could risk the study's safety.Check my eligibility

What is being tested?

The trial is testing the safety and effectiveness of a new treatment called IMG-007 specifically for adults with severe AA. The main goal is to see how safe it is and how the body processes it.See study design

What are the potential side effects?

While specific side effects are not listed here, common ones in trials like this may include skin reactions at the application site, headaches, fatigue, and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 65 years old.

Select...

Over half of my scalp has hair loss.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, week 24

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, week 24

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Evaluation of Adverse Events in Participants

Secondary outcome measures

Evaluation of Severity of Alopecia Tool (SALT)

Pharmacokinetic characterization

Trial Design

2Treatment groups

Experimental Treatment

Group I: IMG-007 Dose 2Experimental Treatment1 Intervention

IMG-007 Dose 2 will be administered intravenously 3 times over 4 weeks

Group II: IMG-007 Dose 1Experimental Treatment1 Intervention

IMG-007 Dose 1 will be administered intravenously 3 times over 4 weeks

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Inmagene LLCLead Sponsor

5 Previous Clinical Trials

220 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age restriction for this research project extend beyond 65?

"This trial is open to all adults aged 18-65."

Answered by AI

Can I join this medical research endeavor?

"Those who wish to participate in this trial must have alopecia areata and be between 18-65 years old. This clinical study has an allocated quota of 30 participants."

Answered by AI

Are enrollees being accepted for this study at present?

"Yes indeed, according to clinicaltrials.gov this trial is currently in search of participants. Initially posted on September 1st 2023 and most recently revised on the 27th of that same month, this study requires 30 volunteers from 9 distinct hospital sites."

Answered by AI

How many participants are able to join the current trial?

"This trial requires 30 suitable individuals to take part. Specifically, the Dawes Fretzin Clinical Resarch Group based in Indianapolis, Indiana and Options Research Group situated in West Lafayette, Texas are two of many possible locations for participation."

Answered by AI

How many medical institutions are engaged in this experiment?

"Dawes Fretzin Clinical Research Group LLC in Indianapolis, Options Research Group in West Lafayette and Stride Clinical Research LLC in Sugar Land are 3 of the 10 participating clinical trial venues."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

2023. "A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06060977.

All > Androgenetic Alopecia > Spokane